← Back to headlines
AbbVie Expands Oncology Pipeline With New BPDCN Treatment Approval
AbbVie Inc. is expanding its oncology pipeline following the approval of a new treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
2 Jun, 13:55 — 2 Jun, 13:55
Sources
Showing 1 of 1 sources
